% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Salomon:353131,
      author       = {Salomon, Nadja and Helm, Alexander and Selmi, Abderaouf and
                      Fournier, Claudia and Diken, Mustafa and Schrörs, Barbara
                      and Scholz, Michael and Kreiter, Sebastian and Durante,
                      Marco and Vascotto, Fulvia},
      title        = {{C}arbon {I}on and {P}hoton {R}adiation {T}herapy {S}how
                      {E}nhanced {A}ntitumoral {T}herapeutic {E}fficacy {W}ith
                      {N}eoantigen {RNA}-{LPX} {V}accines in {P}reclinical {C}olon
                      {C}arcinoma {M}odels},
      journal      = {International journal of radiation oncology, biology,
                      physics},
      volume       = {119},
      number       = {3},
      issn         = {0360-3016},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {GSI-2024-00796},
      pages        = {936 - 945},
      year         = {2024},
      note         = {This is an open access article under the CC BY license
                      (http://creativecommons.org/licenses/by/4.0/)},
      abstract     = {Personalized liposome-formulated mRNA vaccines (RNA-LPX)
                      are a powerful new tool in cancer immunotherapy. In
                      preclinical tumor models, RNA-LPX vaccines are known to
                      achieve potent results when combined with conventional X-ray
                      radiation therapy (XRT). Densely ionizing radiation used in
                      carbon ion radiation therapy (CIRT) may induce distinct
                      effects in combination with immunotherapy compared with
                      sparsely ionizing X-rays.Within this study, we investigate
                      the potential of CIRT and isoeffective doses of XRT to
                      mediate tumor growth inhibition and survival in murine colon
                      adenocarcinoma models in conjunction with neoantigen
                      (neoAg)-specific RNA-LPX vaccines encoding both major
                      histocompatibility complex (MHC) class I- and class
                      II-restricted tumor-specific neoantigens. We characterize
                      tumor immune infiltrates and antigen-specific T cell
                      responses by flow cytometry and interferon-γ enzyme-linked
                      immunosorbent spot (ELISpot) analyses, respectively.NeoAg
                      RNA-LPX vaccines significantly potentiate radiation
                      therapy-mediated tumor growth inhibition. CIRT and XRT alone
                      marginally prime neoAg-specific T cell responses detected in
                      the tumors but not in the blood or spleens of mice.
                      Infiltration and cytotoxicity of neoAg-specific T cells is
                      strongly driven by RNA-LPX vaccines and is accompanied by
                      reduced expression of the inhibitory markers PD-1 and Tim-3
                      on these cells. The neoAg RNA-LPX vaccine shows similar
                      overall therapeutic efficacy in combination with both CIRT
                      and XRT, even if the physical radiation dose is lower for
                      carbon ions than for X-rays.We hence conclude that the
                      combination of CIRT and neoAg RNA-LPX vaccines is a
                      promising strategy for the treatment of radioresistant
                      tumors.},
      keywords     = {Animals / Colonic Neoplasms: radiotherapy / Colonic
                      Neoplasms: immunology / Mice / Cancer Vaccines: therapeutic
                      use / Cancer Vaccines: immunology / Antigens, Neoplasm:
                      immunology / Heavy Ion Radiotherapy: methods / Photons:
                      therapeutic use / Female / Adenocarcinoma: radiotherapy /
                      Adenocarcinoma: immunology / Combined Modality Therapy:
                      methods / Liposomes / mRNA Vaccines: therapeutic use / Cell
                      Line, Tumor / Immunotherapy: methods / RNA, Messenger /
                      Mice, Inbred C57BL / Cancer Vaccines (NLM Chemicals) /
                      Antigens, Neoplasm (NLM Chemicals) / Liposomes (NLM
                      Chemicals) / mRNA Vaccines (NLM Chemicals) / RNA, Messenger
                      (NLM Chemicals)},
      cin          = {BIO / BIO@FAIR},
      ddc          = {610},
      cid          = {I:(DE-Ds200)BIO-20160831OR354 / I:(DE-Ds200)Coll-FAIR-BIO},
      pnm          = {633 - Life Sciences – Building Blocks of Life: Structure
                      and Function (POF4-633) / SUC-GSI-Darmstadt - Strategic
                      university cooperation GSI-TU Darmstadt (SUC-GSI-DA) / FAIR
                      Phase-0 - FAIR Phase-0 Research Program (GSI-FAIR-Phase-0)},
      pid          = {G:(DE-HGF)POF4-633 / G:(DE-Ds200)SUC-GSI-DA /
                      G:(Ds200)GSI-FAIR-Phase-0},
      experiment   = {$EXP:(DE-Ds200)SBio08_Salomon-20200803$},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38163521},
      UT           = {WOS:001263754200001},
      doi          = {10.1016/j.ijrobp.2023.12.042},
      url          = {https://repository.gsi.de/record/353131},
}